Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Epigral Limited (EPIGRAL.NS)
Ahmedabad, GU, IN
Epigral Limited operates in the chemical sector, focusing on the production and global distribution of chlor-alkali products and their associated derivatives. Its diverse product range encompasses chlorinated polyvinyl chloride (CPVC) resins, epichlorohydrin, chloromethanes, hydrogen peroxide, caustic soda, chlorine, hydrogen, and caustic potash. Additionally, the company is involved in the trading of agrochemical products. Epigral caters to an extensive list of industries, including CPVC pipes and fittings, wind energy, construction, paints and coatings, electronics, water treatment, agrochemicals, pharmaceuticals, refineries, soaps and detergents, fluoropolymers, paper and pulp, textiles, alumina, polyurethane foam, lithium, and polytetrafluoroethylene (PTFE) pipes. Incorporated in 2007 and based in Ahmedabad, India, the company was formerly known as Meghmani Finechem Limited until it adopted the name Epigral Limited in August 2023.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.97% | -6.79% | +15.76% | +26.85% | -16.95% | +4.20% | -30.94% | +33.13% | +212.81% | +212.81% | +212.81% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%-0.9% Q1'26: +17.3% (vs Q1'25)
-
EPS growth Chemicals: +11.7%-9.1% Q1'26: -6.9% (vs Q1'25)
-
FCF margin FCF growth · Chemicals: +41.7%+10.0% ★ Q1'26: +4.3% (vs Q1'25)
-
EBIT margin Chemicals: +7.1%+15.8% ★ Q1'26: +17.2% (vs Q1'25)
-
ROIC Chemicals: +3.4%+13.9% ★ Q1'26: +13.5% (vs Q1'25)
-
Share dilution Chemicals: +0.0%+2.1% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×1.01× Q1'26: 0.85× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
21.69B
est: 22.95B (-5.5%)
|
18.94B
est: 19.99B (-5.3%)
|
25.50B
est: 25.85B (-1.3%)
|
24.26B
24.26B – 24.26B
-6.1% YoY
|
30.13B
30.13B – 30.13B
+24.2% YoY
|
38.43B
38.43B – 38.43B
+27.5% YoY
|
| EBITDA |
6.81B
est: 6.84B (-0.4%)
|
4.77B
est: 5.95B (-19.9%)
|
7.11B
est: 7.20B (-1.2%)
|
6.75B
6.75B – 6.75B
-6.1% YoY
|
8.39B
8.39B – 8.39B
+24.2% YoY
|
10.70B
10.70B – 10.70B
+27.5% YoY
|
| EBIT |
5.72B
est: 5.40B (+5.9%)
|
3.53B
est: 4.71B (-25.0%)
|
5.78B
est: 5.70B (+1.4%)
|
5.35B
5.35B – 5.35B
-6.1% YoY
|
6.65B
6.65B – 6.65B
+24.2% YoY
|
8.48B
8.48B – 8.48B
+27.5% YoY
|
| Net Income |
3.53B
est: 3.66B (-3.4%)
|
1.96B
est: 1.87B (+4.9%)
|
3.58B
est: 3.52B (+1.6%)
|
3.33B
2.31B – 3.71B
-5.5% YoY
|
3.13B
3.13B – 3.13B
-6.1% YoY
|
4.61B
4.61B – 4.61B
+47.4% YoY
|
| SGA |
356.34M
est: 355.59M (+0.2%)
|
326.57M
est: 309.67M (+5.5%)
|
501.40M
est: 847.92M (-40.9%)
|
795.89M
795.89M – 795.89M
-6.1% YoY
|
988.50M
988.50M – 988.50M
+24.2% YoY
|
1.26B
1.26B – 1.26B
+27.5% YoY
|
| EPS |
85.03
est: 86.60 (-1.8%)
|
47.14
est: 44.20 (+6.7%)
|
84.68
est: 81.60 (+3.8%)
|
53.50
53.50 – 85.93
-34.4% YoY
|
72.45
72.45 – 72.45
+35.4% YoY
|
106.80
106.80 – 106.80
+47.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 92.3K | 0.65% |
| 2 | State Street SPDR S&P Emerging Asia Pacific ETF GMF | 0.00% | 19.2K | 0.49% |
| 3 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.00% | 173.4K | 0.07% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kaushal Ashisbhai Soparkar | Chief Executive Officer & Executive Director | 8M | male |
| Maulik Jayantibhai Patel | Chairman & MD | 8M | male |
| Milind Kotecha | Investor Relations Officer | — | male |
| Naresh Kumar Agarwal | Senior General Manager of Marketing | — | — |
| R. S. Rajan | Senior Vice President of Power Plant | — | — |
| Rakesh Agrawal | Chief Financial Officer | — | male |
| Vijay Vasudeva | Senior Vice President of Operations | — | — |
| Amritlal Rathod | Head of H2O2 Process | — | — |
| Vikram Bhatt | Senior General Manager of Corporate Human Relations | — | male |
| Gaurang G. Trivedi | Company Secretary & Compliance Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EPIGRAL.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
